Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.

Nowacek AS, McMillan J, Miller R, Anderson A, Rabinow B, Gendelman HE.

J Neuroimmune Pharmacol. 2010 Dec;5(4):592-601. doi: 10.1007/s11481-010-9198-7. Epub 2010 Mar 17.

2.

Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections.

Puligujja P, McMillan J, Kendrick L, Li T, Balkundi S, Smith N, Veerubhotla RS, Edagwa BJ, Kabanov AV, Bronich T, Gendelman HE, Liu XM.

Nanomedicine. 2013 Nov;9(8):1263-73. doi: 10.1016/j.nano.2013.05.003. Epub 2013 May 13.

3.

Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.

Nowacek AS, Balkundi S, McMillan J, Roy U, Martinez-Skinner A, Mosley RL, Kanmogne G, Kabanov AV, Bronich T, Gendelman HE.

J Control Release. 2011 Mar 10;150(2):204-11. doi: 10.1016/j.jconrel.2010.11.019. Epub 2010 Nov 23.

4.

Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages.

Araínga M, Guo D, Wiederin J, Ciborowski P, McMillan J, Gendelman HE.

Retrovirology. 2015 Jan 22;12:5. doi: 10.1186/s12977-014-0133-5.

5.

NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.

Nowacek AS, Miller RL, McMillan J, Kanmogne G, Kanmogne M, Mosley RL, Ma Z, Graham S, Chaubal M, Werling J, Rabinow B, Dou H, Gendelman HE.

Nanomedicine (Lond). 2009 Dec;4(8):903-17. doi: 10.2217/nnm.09.71.

6.

Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.

Dash PK, Gendelman HE, Roy U, Balkundi S, Alnouti Y, Mosley RL, Gelbard HA, McMillan J, Gorantla S, Poluektova LY.

AIDS. 2012 Nov 13;26(17):2135-44. doi: 10.1097/QAD.0b013e328357f5ad.

7.

Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.

Balkundi S, Nowacek AS, Veerubhotla RS, Chen H, Martinez-Skinner A, Roy U, Mosley RL, Kanmogne G, Liu X, Kabanov AV, Bronich T, McMillan J, Gendelman HE.

Int J Nanomedicine. 2011;6:3393-404. doi: 10.2147/IJN.S27830. Epub 2011 Dec 20.

8.

Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.

Guo D, Zhang G, Wysocki TA, Wysocki BJ, Gelbard HA, Liu XM, McMillan JM, Gendelman HE.

J Virol. 2014 Sep 1;88(17):9504-13. doi: 10.1128/JVI.01557-14. Epub 2014 Jun 11.

9.

Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.

Gautam N, Roy U, Balkundi S, Puligujja P, Guo D, Smith N, Liu XM, Lamberty B, Morsey B, Fox HS, McMillan J, Gendelman HE, Alnouti Y.

Antimicrob Agents Chemother. 2013 Jul;57(7):3110-20. doi: 10.1128/AAC.00267-13. Epub 2013 Apr 22.

10.

Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.

Kanmogne GD, Singh S, Roy U, Liu X, McMillan J, Gorantla S, Balkundi S, Smith N, Alnouti Y, Gautam N, Zhou Y, Poluektova L, Kabanov A, Bronich T, Gendelman HE.

Int J Nanomedicine. 2012;7:2373-88. doi: 10.2147/IJN.S29454. Epub 2012 May 8.

11.

Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.

Röshammar D, Simonsson US, Ekvall H, Flamholc L, Ormaasen V, Vesterbacka J, Wallmark E, Ashton M, Gisslén M.

J Pharmacokinet Pharmacodyn. 2011 Dec;38(6):727-42. doi: 10.1007/s10928-011-9217-1. Epub 2011 Oct 2.

PMID:
21964996
12.

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW; AIDS Clinical Trials Group 5201 Study Team..

JAMA. 2006 Aug 16;296(7):806-14.

PMID:
16905786
13.

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.

Di Biagio A, Prinapori R, Giannarelli D, Maggiolo F, Di Giambenedetto S, Borghi V, Penco G, Cicconi P, Francisci D, Sterrantino G, Zoncada A, Monno L, Capetti A, Giacometti A; ARCA Collaborative Group..

J Antimicrob Chemother. 2013 Jan;68(1):200-5. doi: 10.1093/jac/dks339. Epub 2012 Aug 21.

PMID:
22915463
14.

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

Le Tiec C, Barrail A, Goujard C, Taburet AM.

Clin Pharmacokinet. 2005;44(10):1035-50. Review.

PMID:
16176117
15.

Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.

King JR, Yogev R, Jean-Philippe P, Graham B, Wiznia A, Britto P, Carey V, Hazra R, Acosta EP; P1058 Protocol Team..

Antimicrob Agents Chemother. 2011 Sep;55(9):4290-4. doi: 10.1128/AAC.01334-10. Epub 2011 Jun 13.

16.

Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity.

Martinez-Skinner AL, Veerubhotla RS, Liu H, Xiong H, Yu F, McMillan JM, Gendelman HE.

J Proteome Res. 2013 May 3;12(5):2282-94. doi: 10.1021/pr400185w. Epub 2013 Apr 17.

17.

UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.

Huang J, Gautam N, Bathena SP, Roy U, McMillan J, Gendelman HE, Alnouti Y.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Aug 1;879(23):2332-8. doi: 10.1016/j.jchromb.2011.06.032. Epub 2011 Jul 1.

18.

Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.

Puligujja P, Balkundi SS, Kendrick LM, Baldridge HM, Hilaire JR, Bade AN, Dash PK, Zhang G, Poluektova LY, Gorantla S, Liu XM, Ying T, Feng Y, Wang Y, Dimitrov DS, McMillan JM, Gendelman HE.

Biomaterials. 2015 Feb;41:141-50. doi: 10.1016/j.biomaterials.2014.11.012. Epub 2014 Dec 9.

19.

The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy.

Zhang G, Guo D, Dash PK, Araínga M, Wiederin JL, Haverland NA, Knibbe-Hollinger J, Martinez-Skinner A, Ciborowski P, Goodfellow VS, Wysocki TA, Wysocki BJ, Poluektova LY, Liu XM, McMillan JM, Gorantla S, Gelbard HA, Gendelman HE.

Nanomedicine. 2016 Jan;12(1):109-22. doi: 10.1016/j.nano.2015.09.009. Epub 2015 Oct 22.

20.

Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice.

Puligujja P, Araínga M, Dash P, Palandri D, Mosley RL, Gorantla S, Poluektova L, McMillan J, Gendelman HE.

Antiviral Res. 2015 Aug;120:85-8. doi: 10.1016/j.antiviral.2015.05.009. Epub 2015 May 27.

Supplemental Content

Support Center